Edition:
India

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

16.06USD
10:43pm IST
Change (% chg)

$-0.15 (-0.93%)
Prev Close
$16.21
Open
$16.20
Day's High
$16.20
Day's Low
$15.82
Volume
61,843
Avg. Vol
272,851
52-wk High
$17.21
52-wk Low
$11.06

Select another date:

Tue, Feb 13 2018

BRIEF-Sarissa Capital Reconstitutes Innoviva Board

* JULES HAIMOVITZ, SARAH SCHLESINGER, AND MARK DIPAOLO WILL BE ADDED TO INNOVIVA BOARD Source text for Eikon:

BRIEF-Innoviva Enteres Into Agreement With Sarissa Capital Management

* INNOVIVA INC - ENTERED INTO AN AGREEMENT WITH SARISSA CAPITAL MANAGEMENT LP, AND CERTAIN OF ITS AFFILIATES

Drug company Innoviva settles with activist hedge fund Sarissa: sources

U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

Drug company Innoviva settles with activist hedge fund Sarissa -sources

Feb 12 U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

BRIEF-Innoviva Reports Q4 Adj Earnings Per Share $0.55

* INNOVIVA REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Innoviva Appoints Eric D'Esparbes As Co's Interim Principal Executive Officer

* INNOVIVA SAYS ON FEB 7, CO ANNOUNCED APPOINTMENT OF ERIC D'ESPARBES AS CO'S INTERIM PRINCIPAL EXECUTIVE OFFICER, EFFECTIVE FEB 6 - SEC FILING

BRIEF-GSK and Innoviva announce positive data from COPD study

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Innoviva reports Q3 adj earnings $0.31/shr

* Innoviva reports third quarter 2017 financial results and provides business updates

BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD

* CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).

Select another date: